200 related articles for article (PubMed ID: 37236032)
1. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
Kim J; Kim SI; Kim NR; Kim H; Kim HS; Chung HH; Kim JW; Lee C; Lee M
Gynecol Oncol; 2023 Jul; 174():231-238. PubMed ID: 37236032
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of prognostic potential of β-catenin and L1CAM expression according to endometrial cancer risk group.
Yoon H; Suh DH; Kim K; No JH; Kim YB; Kim H
Gynecol Oncol; 2024 Feb; 184():132-138. PubMed ID: 38309030
[TBL] [Abstract][Full Text] [Related]
4. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile.
Kommoss FK; Karnezis AN; Kommoss F; Talhouk A; Taran FA; Staebler A; Gilks CB; Huntsman DG; Krämer B; Brucker SY; McAlpine JN; Kommoss S
Br J Cancer; 2018 Aug; 119(4):480-486. PubMed ID: 30050154
[TBL] [Abstract][Full Text] [Related]
5. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
[No Abstract] [Full Text] [Related]
6. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
[TBL] [Abstract][Full Text] [Related]
7. p53, Pirh2, and L1CAM as Promising Prognostic Biomarkers of Endometrial Carcinoma: An Immunohistochemical and Genetic Study.
Abdelrahman AE; Salem A; Al Attar AZ; Elsebai E; Samy W; Ibrahim MA; Ibrahim HM
Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):713-725. PubMed ID: 36251972
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
Zong L; Sun Z; Mo S; Lu Z; Yu S; Xiang Y; Chen J
Gynecol Oncol; 2021 Sep; 162(3):631-637. PubMed ID: 34272092
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study.
Victoor J; Borght SV; Spans L; Lehnert S; Brems H; Laenen A; Vergote I; Van Gorp T; Van Nieuwenhuysen E; Han S; Timmerman S; Van Rompuy AS; Vanden Bempt I
Gynecol Oncol; 2021 Sep; 162(3):694-701. PubMed ID: 34253388
[TBL] [Abstract][Full Text] [Related]
10. The prognosis of endometrial cancers stratified with conventional risk factors and modified molecular classification.
Yamazaki H; Asano H; Hatanaka KC; Matsuoka R; Konno Y; Matsuno Y; Hatanaka Y; Watari H
Cancer Sci; 2022 Sep; 113(9):3134-3147. PubMed ID: 35707843
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification.
Karnezis AN; Leung S; Magrill J; McConechy MK; Yang W; Chow C; Kobel M; Lee CH; Huntsman DG; Talhouk A; Kommoss F; Gilks CB; McAlpine JN
J Pathol Clin Res; 2017 Oct; 3(4):279-293. PubMed ID: 29085668
[TBL] [Abstract][Full Text] [Related]
12. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
[TBL] [Abstract][Full Text] [Related]
13. Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer.
van Esterik M; Van Gool IC; de Kroon CD; Nout RA; Creutzberg CL; Smit VTHBM; Bosse T; Stelloo E
Oncotarget; 2017 Apr; 8(15):25542-25551. PubMed ID: 28424422
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Risk Stratification in Early-Stage Endometrial Cancer: Integrating
Joe S; Lee M; Kang J; Kim J; Hong SH; Lee SJ; Lee KH; Lee A
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835593
[TBL] [Abstract][Full Text] [Related]
15. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
16. L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB.
Klat J; Mladenka A; Dvorackova J; Bajsova S; Simetka O
Anticancer Res; 2019 Jan; 39(1):421-424. PubMed ID: 30591489
[TBL] [Abstract][Full Text] [Related]
17. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.
de Freitas D; Aguiar FN; Anton C; Bacchi CE; Carvalho JP; Carvalho FM
PLoS One; 2018; 13(12):e0209294. PubMed ID: 30557309
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer.
Zong L; Mo S; Sun Z; Lu Z; Yu S; Chen J; Xiang Y
Mod Pathol; 2022 Feb; 35(2):266-273. PubMed ID: 34493823
[TBL] [Abstract][Full Text] [Related]
19. Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers.
Corrado G; Laquintana V; Loria R; Carosi M; de Salvo L; Sperduti I; Zampa A; Cicchillitti L; Piaggio G; Cutillo G; Falcioni R; Vizza E
J Exp Clin Cancer Res; 2018 Jul; 37(1):139. PubMed ID: 29980240
[TBL] [Abstract][Full Text] [Related]
20. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer.
Chung YS; Woo HY; Lee JY; Park E; Nam EJ; Kim S; Kim SW; Kim YT
Am J Obstet Gynecol; 2021 Apr; 224(4):370.e1-370.e13. PubMed ID: 33039397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]